The delay in issuance of a revised draft that includes preferential drug pricing measures for domestic new drugs is raising concerns in the pharmaceutical industry.

This month, a revised draft that reflects the innovative value of new drugs was released by the Health Insurance Review and Assessment Service, but the revision lacked a measure for homegrown new drugs.

The preferential treatment for such homegrown new drugs was expected to be included in the amendment to the Ministry of Health and Welfare’s “Criteria for Decision or Adjustment on Drugs,” but it is difficult to predict when the notification of the amendment will be issued due to the recent change in the Director Divis